Evidence map›Paper›PMID 40852120›Full record

ArticleMicrobiome research reports2025

Microbiome as a predictive biomarker in locally advanced rectal cancer.

Núria Mulet Margalef, Berta Martín Abad, Eva Martínez-Balibrea, Jose Luís Manzano Mozo, Alessandra Borgognone, Mireia Obón-Santacana

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiome research reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Indole-3-Carbaldehyde fromResearch (Washington, D.C.) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Núria Mulet MargalefMedical Oncology Department, Catalan Institute of Oncology (ICO), Badalona 08916, Spain.
Berta Martín AbadGermans Trias i Pujol Institute (IGTP), Translational Program in Cancer Research (CARE), Badalona 08916, Spain.
Eva Martínez-BalibreaGermans Trias i Pujol Institute (IGTP), Translational Program in Cancer Research (CARE), Badalona 08916, Spain.
Jose Luís Manzano MozoMedical Oncology Department, Catalan Institute of Oncology (ICO), Badalona 08916, Spain.
Alessandra BorgognoneIrsiCaixa, Hospital Universitari Germans Trias i Pujol, Badalona 08916, Spain.
Mireia Obón-SantacanaUnit of Biomarkers and Suceptibility (UBS), Oncology Data Analytics Program (ODAP), Catalan Institute of Oncology (ICO), L'Hospitalet del Llobregat, Barcelona 08908, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The incidence of locally advanced rectal cancer (LARC) among young people is rising alarmingly. In recent years, new protocols have been introduced for the management of LARC, some of which are associated with the risk of significant toxicity. Despite these advancements, robust predictive biomarkers for LARC have yet to be established. The microbiome has emerged as a potential biomarker due to its interaction with tumor multiomics. This article provides a critical overview of the current evidence on the microbiome and LARC, including its relationship with the immune system and epigenomics, and also highlights both the current limitations and future perspectives in the field.

Indexed as

epigenomicsexposomeFusobacterium nucleatumlocally advanced rectal cancerMicrobiome

Identifiers

PMID40852120
PMCPMC12367463

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.